Patient characteristics
| Characteristics . | All patients (n = 27) . |
|---|---|
| Age, median (range), y | 33 (15-67) |
| Hodgkin type | |
| Nodular sclerosis type | 18 (67%) |
| Mixed cellularity | 4 (15%) |
| Unspecified | 5 (18%) |
| Sex (male) | 18 (67%) |
| Disease stage | |
| I-II | 9 (33%) |
| III-IV | 18 (67%) |
| Prior therapies | |
| Median (range) | 8 (3-23) |
| Prior AutoSCT | 22 (81%) |
| Prior AlloSCT | 10 (37%) |
| Bridging therapy | 19 (70%) |
| Bridging response | |
| Complete response | 5 (26%) |
| Partial response | 6 (32%) |
| Stable disease | 8 (42%) |
| Lymphodepletion regimen | |
| Benda | 8 (30%) |
| Benda/Flu | 19 (70%) |
| CD30.CAR-T dose | |
| 1 × 108 cells/m2 | 5 (19%) |
| 2 × 108 cells/m2 | 22 (81%) |
| CD30.CAR-T response | |
| Complete response | 18 (67%) |
| Partial response | 1 (4%) |
| Stable disease | 2 (7%) |
| Progressive disease | 6 (22%) |
| Characteristics . | All patients (n = 27) . |
|---|---|
| Age, median (range), y | 33 (15-67) |
| Hodgkin type | |
| Nodular sclerosis type | 18 (67%) |
| Mixed cellularity | 4 (15%) |
| Unspecified | 5 (18%) |
| Sex (male) | 18 (67%) |
| Disease stage | |
| I-II | 9 (33%) |
| III-IV | 18 (67%) |
| Prior therapies | |
| Median (range) | 8 (3-23) |
| Prior AutoSCT | 22 (81%) |
| Prior AlloSCT | 10 (37%) |
| Bridging therapy | 19 (70%) |
| Bridging response | |
| Complete response | 5 (26%) |
| Partial response | 6 (32%) |
| Stable disease | 8 (42%) |
| Lymphodepletion regimen | |
| Benda | 8 (30%) |
| Benda/Flu | 19 (70%) |
| CD30.CAR-T dose | |
| 1 × 108 cells/m2 | 5 (19%) |
| 2 × 108 cells/m2 | 22 (81%) |
| CD30.CAR-T response | |
| Complete response | 18 (67%) |
| Partial response | 1 (4%) |
| Stable disease | 2 (7%) |
| Progressive disease | 6 (22%) |
AlloSCT, allogeneic stem cell transplant; AutoSCT, autologous stem cell transplant; Benda, bendamustine; Flu, fludarabine.